Fuks B - Search Results

1

Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines.

Fuks B, Gillard M, Michel P, Lynch B, Vertongen P, Leprince P, Klitgaard H, Chatelain P. Fuks B, et al. Eur J Pharmacol. 2003 Sep 30;478(1):11-9. doi: 10.1016/j.ejphar.2003.08.033. Eur J Pharmacol. 2003. PMID: 14555179

2

Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain.

Gillard M, Fuks B, Michel P, Vertongen P, Massingham R, Chatelain P. Gillard M, et al. Among authors: fuks b. Eur J Pharmacol. 2003 Sep 30;478(1):1-9. doi: 10.1016/j.ejphar.2003.08.032. Eur J Pharmacol. 2003. PMID: 14555178

3

[3H]linopirdine binding to rat brain membranes is not relevant for M-channel interaction.

Wolff C, Gillard M, Fuks B, Chatelain P. Wolff C, et al. Among authors: fuks b. Eur J Pharmacol. 2005 Jul 25;518(1):10-7. doi: 10.1016/j.ejphar.2005.06.005. Eur J Pharmacol. 2005. PMID: 16018996

4

Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord.

Lambeng N, Gillard M, Vertongen P, Fuks B, Chatelain P. Lambeng N, et al. Among authors: fuks b. Eur J Pharmacol. 2005 Sep 27;520(1-3):70-6. doi: 10.1016/j.ejphar.2005.07.029. Eur J Pharmacol. 2005. PMID: 16125696

5

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.

Gillard M, Chatelain P, Fuks B. Gillard M, et al. Among authors: fuks b. Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. doi: 10.1016/j.ejphar.2006.02.022. Epub 2006 Mar 10. Eur J Pharmacol. 2006. PMID: 16556440

6

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

Gillard M, Fuks B, Leclercq K, Matagne A. Gillard M, et al. Among authors: fuks b. Eur J Pharmacol. 2011 Aug 16;664(1-3):36-44. doi: 10.1016/j.ejphar.2011.04.064. Epub 2011 May 8. Eur J Pharmacol. 2011. PMID: 21575627

7

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P. Kenda BM, et al. Among authors: fuks b. J Med Chem. 2004 Jan 29;47(3):530-49. doi: 10.1021/jm030913e. J Med Chem. 2004. PMID: 14736235

8

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. Lynch BA, et al. Among authors: fuks b. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. doi: 10.1073/pnas.0308208101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210974 Free PMC article.

9

Failure of GPI compounds to display neurotrophic activity in vitro and in vivo.

Bocquet A, Lorent G, Fuks B, Grimée R, Talaga P, Daliers J, Klitgaard H. Bocquet A, et al. Among authors: fuks b. Eur J Pharmacol. 2001 Mar;415(2-3):173-80. doi: 10.1016/s0014-2999(01)00850-0. Eur J Pharmacol. 2001. PMID: 11274996

10

Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties.

Lambeng N, Grossmann M, Chatelain P, Fuks B. Lambeng N, et al. Among authors: fuks b. Neurosci Lett. 2006 May 1;398(1-2):107-12. doi: 10.1016/j.neulet.2005.12.059. Epub 2006 Jan 24. Neurosci Lett. 2006. PMID: 16434140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters